GlassScriptPhysician profile
Zeba Syed
NPI 1801874730
$3,860.85
in general payments reported to CMS, 2019-2025
13 companies · $898 in 2025
The $898 reported for 2025 was more than what 84% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.58 · 2021: $25.36 · 2022: $105 · 2023: $1,872 · 2024: $949 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,250 · Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,250.00 |
| Food and Beverage | $469.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,250.00 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $223.96 | 2022-2024 | Cequa |
| Dompe US, INC. | $135.66 | 2022-2025 | Oxervate |
| Harrow Eye, LLC | $66.77 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $33.40 | 2024 | |
| Bausch & Lomb Americas INC. | $25.15 | 2025 | Miebo, Xiidra |
| Lunit Americas, INC. | $24.88 | 2022 | |
| Sight Sciences, INC. | $22.92 | 2025 | Tearcare System |
| Otsuka America Pharmaceutical, INC. | $22.22 | 2024 | Rexulti |
| Abbvie INC. | $18.95 | 2025 | |
| Eyevance Pharmaceuticals LLC | $13.01 | 2021 | |
| Bard Peripheral Vascular, INC. | $12.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeba Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.